Has Nina Jain received payments from drug or device companies?

Yes. Drug and device makers reported $22,348 in general payments to Nina Jain across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nina Jain did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nina Jain come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nina Jain

Pediatric Endocrinology · Sanford, NCNPI 1245443126

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,427 of the $22,348 with a category attached, or 64.6%. Sanofi accounts for 71.2% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $22,176, more than ten times the $108 reported in 2019. Among pediatric endocrinology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,348in general payments, 2019–2025

Across 16 payments — averaging $1396.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$16K
Sanofi-aventis U.S. LLC$6K
Novo Nordisk$108
Ultragenyx Pharmaceutical Inc.$64

$500,479in research payments, 2019–2025

Across 97 payments — averaging $5159.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Ultragenyx Pharmaceutical Inc.$210K
Boehringer Ingelheim$137K
Sanofi$59K
Astrazeneca UK Limited$31K
Boehringer Ingelheim Pharma GmbH & Co.kg$25K
Aeterna Zentaris Inc.$22K
plus $17K from 4 others

What the payments were for

Consulting fees$14,42765%
Speaking & faculty fees$5,91826%
Travel & lodging$1,0004%
Food & beverage$1,0034%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	9	$15,913
Sanofi-aventis U.S. LLC	5	$6,262
Novo Nordisk	1	$108
Ultragenyx Pharmaceutical Inc.	1	$64

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TZIELD$3,724

How this compares

$22,348 in reported general payments places this provider in the 90th percentile of 46 pediatric endocrinology providers in North Carolina.

See all pediatric endocrinology providers in North Carolina →

Other pediatric endocrinology in Sanford

Mark VanderwelCharlotte$42K
Jennifer LawChapel Hill$40K
Jakub MieszczakCharlotte$34K
Olga GuptaDurham$22K
Hillary LockemerRaleigh$18K
Michael StalveyWinston Salem$14K
Rebecca VitaleChapel Hill$5K
Henry RohrsCharlotte$4K
Colette MeehanGreensboro$3K
Michael BrennanGreensboro$3K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →